Health ConditionsDysmenorrhea is defined as difficult menstrual flow or painful menstruation. It can be divided into two broad categories: primary and secondary. Primary dysmenorrhea is defined as menstrual pain that is not associated with macroscopic pelvic pathology — that is, it occurs in the absence of pelvic disease. It typically occurs in the first few years after menarche and affects as many as 50% of postpubertal females.
Secondary dysmenorrhea is defined as menstrual pain resulting from anatomic or macroscopic pelvic pathology, as is seen in women with endometriosis or chronic pelvic inflammatory disease, and is most often observed in women aged 30–45 years. Underlying causes of secondary dysmenorrhea include endometriosis (where tissue similar to the uterine lining grows outside the uterus), uterine fibroids (noncancerous growths in the uterine wall), adenomyosis (where the uterine lining grows into the muscular walls of the uterus), pelvic inflammatory disease (infection of the female reproductive organs usually caused by sexually transmitted bacteria), and cervical stenosis.
The prevalence of dysmenorrhea varies between 16% and 91% in women of reproductive age, with severe pain in 2%–29% of the women studied. About 60% of people with a uterus have mild cramps during their period, while about 5%–15% report period pain so severe it affects their daily activities; this number is likely higher, as healthcare providers believe many people do not report menstrual pain.
The symptoms of primary dysmenorrhea are well characterized in clinical literature. These include aching, throbbing pain in the abdomen (pain may be severe at times), a feeling of pressure in the abdomen, pain in the hips, lower back, and inner thighs, as well as other symptoms such as nausea, dizziness, and headaches. In most cases, the pain begins in the 24 to 48 hours before the period and subsides within 48 hours of onset of bleeding.
Pain from secondary dysmenorrhea usually begins earlier in the menstrual cycle and lasts longer than typical menstrual cramps; cramping may begin several days before the period and the pain may last until bleeding completely stops. Nausea, vomiting, or fatigue are typically not associated with secondary dysmenorrhea.
The pathophysiology of the condition is primarily prostaglandin-driven. At the beginning of menses, prostaglandins are released and play a major role in inducing uterine contractions within the female reproductive system. These contractions lead to uterine ischemia, which stimulates pain neurons resulting in pain. The severity of pain has been studied and correlated with the level of menstrual prostaglandin.
Evidence suggests that the pathogenesis of primary dysmenorrhea is due to prostaglandin F2α (PGF2α), a potent myometrial stimulant and vasoconstrictor, in the secretory endometrium. After the ovulation process occurs in response to increased progesterone production, fatty acids increase in cell membrane phospholipids. Arachidonic acid and other omega-7 fatty acids are then released, initiating the prostaglandin and leukotriene cascade in the uterus. The result of arachidonic acid metabolism is prostaglandin PGF2α, which acts via the cyclooxygenase (COX) pathway to produce hypertonus and vasoconstriction in the myometrium, resulting in ischemia and endometrial death, including damage to blood vessels and menstrual pain.
The uterus contracts throughout the menstrual cycle, and more strongly during menstruation. If the uterus contracts too strongly, it can press against nearby blood vessels, cutting off the oxygen supply to muscle tissue — and pain is felt when part of the muscle briefly loses its supply of oxygen. Because the uterine lining is shed during menstruation, the level of prostaglandins drops during a menstrual period, causing symptoms to ease.
Beyond prostaglandins, vasopressin has also been implicated. The more severe pain in primary dysmenorrhea appears to be the result of a combined effect of vasopressin and PGF2α, both of which are effective uterine stimulants in the non-pregnant human uterus, especially around the onset of menstruation.
The body systems principally involved in dysmenorrhea include: the reproductive system (uterine myometrium and endometrium), the vascular system (endometrial blood vessels subject to prostaglandin-driven vasoconstriction), the endocrine system (hormonal shifts in estrogen and progesterone that regulate prostaglandin synthesis), the immune/inflammatory system (via the arachidonic acid cascade and leukotriene activity), and the central and peripheral nervous systems (pain signaling from ischemic uterine tissue).
A range of risk factors may be associated with primary dysmenorrhea, including biological, psychological, social, and lifestyle factors. Biological factors include early age at menarche, heavy menstrual flow, and family history of dysmenorrhea; psychological factors include stress, anxiety, and depression; social factors include low level of social support; and lifestyle factors include smoking and irregular diet.
Women's age, parity, and use of oral contraceptives are inversely associated with dysmenorrhea, and high stress increases the risk. Effect sizes are generally modest to moderate, with odds ratios varying between 1 and 4. Family history of dysmenorrhea strongly increases its risk, with odds ratios between 3.8 and 20.7. Inconclusive evidence was found for modifiable factors such as cigarette smoking, diet, obesity, depression, and abuse.
A 2024 systematic review and meta-analysis found that adequate sleep was a protective factor for primary dysmenorrhea in female college students, while family history of dysmenorrhea, early age of menarche, irregular menstrual cycle, high caffeine intake, stress, and drinking cold drinks were all identified as risk factors.
A broad meta-analysis additionally found that underweight, skipping breakfast, poor sleep quality, staying up late, lack of physical exercise, exposure to cold and eating cold or spicy foods during menstruation, dietary bias, preference for snacks, irregular menstrual cycle, heavy stress, negative emotion during menstruation, and anxiety were significantly related to primary dysmenorrhea.
One clinical study found that compared to healthy controls, primary dysmenorrhea patients had significantly more menstrual bleeding, more history of maternal dysmenorrhea, lower serum calcium, lower serum 25-hydroxyvitamin D3, and more vitamin D deficiency.
The following section separates traditional use from scientific evidence where applicable. For many nutrients, traditional use is limited or absent — their investigation has been driven primarily by modern clinical science.
Traditional Use: Fish oil and omega-3-rich diets do not have a well-documented classical tradition in the specific treatment of menstrual pain. Their investigation for dysmenorrhea arose from modern understanding of the arachidonic acid cascade and prostaglandin biology.
Proposed Mechanism: Upon consumption, omega-3 fatty acids serve as a substrate for cyclooxygenase enzymes, promoting synthesis of series-3 prostaglandins. As a consequence, the concentration of pro-inflammatory series-2 prostaglandins diminishes while levels of anti-inflammatory series-3 prostaglandins increase. Series-3 prostaglandins help diminish myometrial contractions, alleviating ischemia and discomfort during menstruation.
Scientific Evidence: An early crossover trial enrolled 42 adolescents with dysmenorrhea randomly allocated to two groups; one group received fish oil (1080 mg EPA, 720 mg DHA, and 1.5 mg vitamin E) daily for 2 months followed by placebo for 2 months, while the other group received placebo first, then fish oil. After 2 months of treatment with fish oil, there was a marked reduction in the Cox Menstrual Symptom Scale from a baseline mean of 69.9 to 44.0 (p < 0.0004).
A systematic review and meta-analysis published in 2022 noted that no definitive conclusions had yet been reached on the effect of omega-3 PUFAs on primary dysmenorrhea, and thus conducted a meta-analysis of randomized controlled trials (RCTs) retrieved from PubMed, Scopus, Web of Science, and other databases. The Cochrane Collaboration's Risk of Bias Tool was used for quality assessment, and the random-effects model was applied. The results showed that omega-3 PUFAs reduce the severity of primary dysmenorrhea in women (SMD = −1.075, 95% CI).
A later systematic review noted that its own findings of greater pain reduction with omega-3 long-chain PUFA supplementation compared to control interventions were similar to the earlier meta-analysis, which showed a mean pain reduction of 1.075 cm on a 10-cm visual analogue scale — although due to the small number of studies, the findings were heavily influenced by a single paper. Overall, the evidence for omega-3 supplementation in dysmenorrhea is promising but still limited by small, heterogeneous trials.
Traditional Use: Vitamin D is not traditionally associated with menstrual pain management. Its relevance emerged from epidemiological observations of deficiency in dysmenorrhea populations.
Scientific Evidence: Studies indicate that vitamin D can reduce the severity of menstrual pain by decreasing the synthesis of prostaglandins, which are key mediators of pain and inflammation. One clinical study found significantly lower serum 25-hydroxyvitamin D3 and more vitamin D deficiency in primary dysmenorrhea patients compared to healthy controls. A systematic review and meta-analysis of micronutrients found that vitamins D, K, B1, and E, as well as calcium, magnesium, zinc sulfate, and boron, contributed effectively to dysmenorrhea pain management. Two months after the intervention, there was a significant mean decrease in pain score for the vitamin D intervention group (SMD: −1.02, 95% CI: −1.9 to −0.14, P = 0.024). Despite the paucity of related research, the studies indicated the potential effects of micronutrients on reducing pain severity in primary dysmenorrhea. Evidence is rated as preliminary to moderate; most individual trials are small.
Scientific Evidence: Calcium has been shown to reduce muscle contractions, which can alleviate the intensity of menstrual cramps. A systematic review found that vitamin D, calcium (and magnesium), zinc, and curcumin were effective in reducing pain or severity of menstrual-related symptoms. A maximum of three papers were reviewed under each of these interventions, and therefore, despite positive results, the evidence base is limited. Lower serum calcium levels have been documented in primary dysmenorrhea patients compared to healthy controls. The evidence is suggestive but requires larger confirmatory trials.
Scientific Evidence: In one clinical study, administration of 200 mg magnesium sulfate to primary dysmenorrhea patients significantly reduced pelvic pain, although not as much as combined oral contraceptive administration, and caused significant reductions in the need for painkillers. The proposed mechanism relates to magnesium's role as a calcium antagonist, which may reduce uterine muscle contractility. Magnesium is among the micronutrients identified in systematic review evidence as contributing effectively to dysmenorrhea pain management. Evidence is limited but consistent with physiological plausibility.
Scientific Evidence: Zinc is recognized for its anti-inflammatory and antioxidant effects through inhibiting prostaglandin production and superoxide dismutase 1 (SOD1) upregulation; it is proposed to alleviate menstrual pain by preventing uterine spasms and enhancing microcirculation in the endometrium. The Cochrane review of dietary supplements for dysmenorrhea found very limited evidence for zinc sulfate (MD −0.95 points, 95% CI: −1.54 to −0.36; one RCT, 99 women). A more recent meta-analysis found that adverse event rates did not differ significantly between zinc and placebo groups (odds ratio = 2.54; 95% CI: 0.78 to 8.26; p = 0.122), suggesting good tolerability. Evidence is preliminary; data derive from a small number of trials.
Scientific Evidence: A systematic review and meta-analysis found a significant mean decrease in pain for the vitamin E intervention group compared to placebo (SMD: −0.47, 95% CI: −0.74 to −0.2, P = 0.001). Vitamin E was among the non-herbal supplements assessed in the Cochrane review of dietary supplements for dysmenorrhea. Evidence is low to moderate quality.
Scientific Evidence: The Cochrane review found very limited but positive evidence for vitamin B1 alone (MD −2.70 points, 95% CI: −3.32 to −2.08; one RCT, 120 women) and for fish oil plus vitamin B1 combined (MD −1.21 points, 95% CI: −1.79 to −0.63; one RCT, 120 women) compared to placebo. Evidence remains very preliminary, based on single small trials.
Traditional Use: Ginger has been used to treat dysmenorrhea in traditional medicine in India, Iran, and Malaysia. In traditional Chinese medicine, dysmenorrhea is attributed to the stagnation of cold dampness in the uterine collaterals caused by the intake of cold drinks or exposure to cold; therapeutic principles focus on warming meridians, dispersing cold, and removing dampness. Ginger, along with cinnamon and fennel, is classified in this system as a warming agent.
Scientific Evidence: A systematic review and meta-analysis of RCTs found suggestive evidence for the effectiveness of 750–2000 mg ginger powder during the first 3–4 days of the menstrual cycle for primary dysmenorrhea. A further systematic review and meta-analysis was performed to evaluate randomized controlled ginger studies for primary dysmenorrhea, with literature searched using PubMed, Embase, Ovid, ClinicalKey, and Medline, comparing ginger with placebo and NSAIDs in women with primary dysmenorrhea, and assessing pain severity and pain duration as primary outcomes. The Cochrane review found very limited evidence of effectiveness for ginger specifically (MD −1.55 points, 95% CI: −2.43 to −0.68; three RCTs, 266 women). Ginger was the most investigated single plant in one review: eight studies assessed the effects of ginger alone, and four studied the combination of ginger with other plants, with all but one showing significant effects. Overall, evidence is rated as low to moderate quality — findings are encouraging but study sizes are small and methodological quality is variable.
Traditional Use: Foeniculum vulgare was used in clinical human trials to treat dysmenorrhea and premenstrual syndrome (PMS); fennel extracts showed more effective results than placebo in pain relief, apparently through the ability to inhibit contractions induced by oxytocin and PGE2 as demonstrated in rat uterus models. Fennel is considered an acceptable herbal treatment for dysmenorrhea given its contrastimulant and analgesic effects.
Scientific Evidence: A meta-analysis of nine studies with 647 patients showed that pain intensity was significantly relieved with fennel versus placebo (WMD = 0.528, 95% CI = 0.119–6.829). However, the Cochrane review concluded there was no high-quality evidence to support the effectiveness of any dietary supplement for dysmenorrhea, though for several supplements there was some low-quality evidence of effectiveness. Evidence for fennel is thus rated as low quality; promising but not conclusive.
Traditional Use: Cinnamon, an aromatic spice, has been used to treat various inflammatory disorders and chronic diseases, including menstrual pain and arthritis. In traditional Chinese medicine, it is classified as a warming herb indicated for cold-type dysmenorrhea.
Scientific Evidence: In the meta-analysis of nine RCTs, pain intensity was significantly relieved with cinnamon versus placebo (WMD = 1.815, 95% CI = 1.330–2.301). Cinnamon, fennel, and ginger can effectively reduce pain intensity in primary dysmenorrhea, with cinnamon also being able to shorten the duration of pain. A later systematic review incorporating 18 studies with 1,372 participants, however, found no significant difference between intervention groups (cinnamon, ginger, or fennel) and control groups in terms of pain severity and duration, highlighting ongoing inconsistency in the literature. Evidence is rated as preliminary and mixed.
Traditional Use: Chamomile has been used in European folk medicine for centuries as an antispasmodic, anti-inflammatory, and calming herb. In Western countries such as the United States, chamomile is regarded as one of the most available herbal alternative therapies for menstrual complaints.
Scientific Evidence: In human trials, a significant difference was noted between the use of Matricaria chamomilla L. and mefenamic acid, with chamomile demonstrating a greater reduction in primary dysmenorrhea pain. The Cochrane review of 27 RCTs involving 3,101 women included chamomile among the 12 herbal medicines assessed for dysmenorrhea. Evidence is rated as preliminary; few high-quality trials exist.
Traditional Use: Since the 11th century, Valeriana officinalis has been used in traditional medicine as a menstruating herb and sedative drug. Its roots contain valerian essential oil with valepotriates, used historically as a sedative, diuretic, and muscular antispasmodic.
Scientific Evidence: The Cochrane review found very limited evidence for valerian (MD −0.76 points, 95% CI: −1.44 to −0.08; one RCT, 100 women) compared to placebo. Studies comparing V. officinalis root with placebo and with mefenamic acid found that pain reduction with valerian was effective compared to placebo, and a similar effect was observed with mefenamic acid. Evidence is rated as very preliminary due to the small number of trials.
Traditional Use: Traditional medicine and Ayurveda have for centuries employed herbs including turmeric to treat a variety of illnesses, exploiting various bioactive compounds. In Ayurvedic medicine, turmeric has been used as an anti-inflammatory and digestive tonic, including for menstrual irregularities.
Proposed Mechanism: Curcumin's anti-inflammatory and analgesic properties make it a promising natural remedy for managing dysmenorrhea; by inhibiting the production of pro-inflammatory mediators, curcumin may help alleviate menstrual cramps and reduce pain intensity and duration. Some studies have indicated that curcumin's pain-relieving effects may be comparable to NSAIDs.
Scientific Evidence: A systematic review found that curcumin, a turmeric extract, shows promise in reducing PMS and dysmenorrhea symptoms through its anti-inflammatory, immunomodulatory, and antioxidant properties; out of ten RCTs, six reported significant symptom improvement, and curcumin positively influences inflammatory biomarkers and vitamin D status. The findings suggest that curcumin holds promise in the management of PMS and dysmenorrhea; however, further research is needed to establish optimal dosages and treatment durations, considering potential interactions with iron metabolism. Recent findings suggest that curcumin demonstrates significant anti-inflammatory effects by suppressing the synthesis of prostaglandins, thereby helping to reduce menstrual pain. Evidence is rated as moderate but requiring confirmation in larger trials; bioavailability of standard curcumin preparations is a known limitation.
Traditional Use: Fenugreek seeds have a long history of use in South Asian and Middle Eastern traditional medicine as a uterine stimulant and for the relief of menstrual pain.
Scientific Evidence: The Cochrane review identified very limited evidence of effectiveness for fenugreek (MD −1.71 points, 95% CI: −2.35 to −1.07; one RCT, 101 women). Evidence is rated as very preliminary.
The Cochrane review of dietary supplements for dysmenorrhea encompassed 12 different herbal medicines — including chamomile, cinnamon, Damask rose, dill, fennel, fenugreek, ginger, guava, rhubarb, uzara, valerian, and zataria — and five non-herbal supplements (fish oil, melatonin, vitamins B1 and E, and zinc sulfate), in a variety of formulations and doses, compared with other supplements, placebo, no treatment, and NSAIDs. There was no high-quality evidence to support the effectiveness of any dietary supplement for dysmenorrhea, and evidence of safety was lacking; however, for several supplements there was some low-quality evidence of effectiveness.
Studies have linked dysmenorrhea/menstrual distress with higher consumption frequency of certain food groups; women with severe dysmenorrhea consumed refined cereal products, processed meat, sugar, and water significantly more frequently. Research has also found that lack of exercise before and during menstruation was associated with increased cramps and mood instability, and that skipping breakfast and consumption of junk food was associated with elevated pain and impact on daily activities.
Diet quality appears relevant to dysmenorrhea in several ways documented in peer-reviewed literature. Skipping breakfast and dietary bias are among the lifestyle-related risk factors associated with primary dysmenorrhea in meta-analyses. High caffeine intake has been confirmed as a risk factor for primary dysmenorrhea in a systematic review and meta-analysis.
Regarding fatty acid composition, the relationship between dietary fat quality and prostaglandin synthesis is mechanistically important: after ovulation, arachidonic acid and other fatty acids are released from cell membrane phospholipids, initiating the prostaglandin and leukotriene cascade in the uterus that mediates inflammation and menstrual cramps. Dietary patterns high in arachidonic acid precursors (e.g., high saturated fat, high omega-6) may theoretically amplify this pathway, though direct dietary intervention evidence in humans remains limited.
Many studies suggest a possible relationship between a low level of physical activity and a greater intensity of menstrual pain, though other studies find no relationship between these variables. Exercise can reduce the activity of the sympathetic nervous system and increase activity of the parasympathetic nerves during rest, reduce stress, and thereby reduce menstrual symptoms. Regular aerobic exercise can reduce pain by increasing the secretion of endorphins, the body's natural opiates.
Thirty minutes of brisk walking per day on the first three days of menstruation has been reported to reduce primary dysmenorrhea pain. Dysmenorrhea was less prevalent in those who had regular exercise three sessions per week compared to those who did not exercise. Among different exercise types, one cross-sectional study found cardio training and flexibility exercises to be the most effective in alleviating menstrual pain, followed by strength training. However, a meta-analysis found that underweight status, physical exercise, and age were not independently associated with primary dysmenorrhea (P > .05) in female college students. Overall, the relationship between exercise and dysmenorrhea is plausible and supported by multiple observational studies, but high-quality RCT evidence specific to exercise type and intensity remains limited.
Adequate sleep has been identified as a protective factor for primary dysmenorrhea in a systematic review and meta-analysis of studies in female college students. Conversely, poor sleep quality and staying up late are significantly related to primary dysmenorrhea in meta-analyses of student populations.
High stress increases the risk of dysmenorrhea, an association confirmed across multiple epidemiological reviews. One study found that elevated prolactin and cortisol levels — both stress-related markers — were independent risk factors for primary dysmenorrhea in logistic regression analysis, highlighting the complex interplay between hormonal regulation, psychological stress, and eating behavior in the condition.
Lifestyle risk factors identified in the literature include smoking and alcohol consumption, alongside diet and physical activity. Contributing risk factors from earlier reviews include younger age, low and high body mass index, earlier age at menarche, smoking, prolonged or aberrant menstrual flow, family history of dysmenorrhea, nulliparity, and high caffeine intake.
A 2025 RCT of standardized A. racemosus root extract in perimenopausal women specifically assessed dysmenorrhea and menstrual cramps via the Menstrual Symptom Questionnaire, with the active group showing significant improvement over placebo. Traditional Ayurvedic use of shatavari for menstrual pain is well-documented.
A 2015 triple-blind RCT (n=113 university students with primary dysmenorrhea, Shahid Beheshti University) found that 10 mg/day boron taken from two days before menstrual flow until the third day of flow significantly reduced both the severity and duration of pain over two consecutive cycles compared to placebo (p=0.001 for severity; p=0.032 for duration).
A 2023 double-blind RCT demonstrated a turmeric–boswellia–sesame formulation provided 12.6 times greater total pain relief than placebo in primary dysmenorrhea. Boswellic acids inhibit 5-lipoxygenase (5-LOX), reducing leukotriene-driven uterine inflammation. Boswellia has traditional Ayurvedic use for gynecological complaints.
Boswellic acids (from Boswellia serrata) specifically inhibit 5-lipoxygenase, reducing leukotriene synthesis involved in uterine inflammation. A 2023 RCT demonstrated a boswellia–turmeric–sesame formulation significantly reduced primary dysmenorrhea pain. Boswellic acids have clinical evidence for anti-inflammatory effects relevant to menstrual cramps.
Clinical research shows a specific combination product containing celery seed, anise, and saffron reduces pain severity and duration during the menstrual cycle. Celery's antispasmodic constituent apiol is traditionally used for menstrual discomfort in Western and Ayurvedic herbal medicine.
A 2021 systematic review of seven clinical trials (n=1033) concluded chamomile is an effective treatment for primary dysmenorrhea, reducing both pain and menstrual bleeding. Chamomile extract inhibits prostaglandin and leukotriene production, which are central to dysmenorrhea pathophysiology. It has centuries of traditional use in European and Middle Eastern herbal medicine for menstrual complaints.
VAC is clinically used in dysmenorrhea, which was the most common menstrual cycle disorder (43.8%) in a real-world cohort of 1700 women; 85.2% of patients reported improvement in menstrual pain after three months of treatment. The mechanism is indirectly progesterogenic, as progesterone modulates uterine prostaglandin production—the primary driver of dysmenorrhea.
Danshen is clinically prescribed in TCM for dysmenorrhea (menstrual pain) and has been studied in RCTs within endometriosis-related pain contexts. Its mechanism is primarily circulatory—promoting pelvic blood flow and resolving stasis—with additional anti-inflammatory effects via tanshinones and salvianolic acids.
RCTs and a 2020 systematic review/meta-analysis confirm cinnamon significantly reduces pain intensity and duration in primary dysmenorrhea versus placebo. A dedicated double-blind RCT showed cinnamon reduced dysmenorrhea intensity. Traditional and Chinese medicine have long used cinnamon to warm the uterus and relieve menstrual pain.
Multiple RCTs and a 2025 systematic review confirm curcumin reduces dysmenorrhea pain and PMS symptoms, with significant effects observed in triple-blind RCTs. Curcumin inhibits COX/LOX pathways, modulates prostaglandin synthesis, and has antioxidant activity. It is the primary active compound in turmeric responsible for anti-dysmenorrhea effects.
EPA reduces dysmenorrhea by competitively inhibiting the production of pro-inflammatory arachidonic acid-derived prostaglandins (PGE2, PGF2α) that drive uterine contractions and pain. Multiple RCTs and a 2010 EMHJ study demonstrate fish oil/EPA supplementation reduces menstrual pain intensity and analgesic requirements.
A 2020 systematic review and meta-analysis of 12 RCTs concluded fennel is as effective as conventional drug therapies in alleviating primary dysmenorrhea pain and more effective than placebo. Its antispasmodic action on uterine smooth muscle has been confirmed in preclinical models. A 2020 multi-database meta-analysis also found it significantly reduces pain intensity.
Fenugreek (Trigonella foenum-graecum) is listed among herbs reported effective for dysmenorrhea in a PMC systematic review. A clinical trial found fenugreek seed powder reduced the severity of primary dysmenorrhea. It contains phytoestrogens and anti-inflammatory compounds with relevance to uterine cramping.
Fish oil supplementation has shown clinically meaningful reductions in primary dysmenorrhea (menstrual cramp) severity in multiple RCTs. The mechanism involves EPA and DHA competing with arachidonic acid to reduce pro-inflammatory prostaglandin E2 and prostaglandin F2α synthesis in the uterus, which are the primary mediators of menstrual pain.
Multiple systematic reviews and meta-analyses of RCTs confirm oral ginger reduces primary dysmenorrhea pain severity compared to placebo, with effect size similar to NSAIDs. Ginger inhibits prostaglandin synthesis via cyclooxygenase and lipoxygenase pathways. Evidence supports 750–2000 mg/day of ginger powder during the first 3–4 days of the menstrual cycle.
GLA influences prostaglandin metabolism through DGLA/PGE1, with PGE1 known to relax smooth muscle and oppose the uterine-contracting prostaglandins central to menstrual pain. A double-blind RCT found GLA supplementation significantly reduced PMS symptom severity in women with documented lower DGLA levels. EPO has a traditional and evidence-based history of use for menstrual symptoms.
A double-blind RCT (Sampalis et al., 2003; n=70 women with PMS/dysmenorrhea) found Neptune Krill Oil (2 g/day for 3 months) significantly reduced dysmenorrhea pain and analgesic use, with effects superior to fish oil. The proposed mechanism is EPA-mediated reduction of pro-inflammatory prostaglandins that cause uterine cramping.
Multiple randomized clinical trials have demonstrated that lavender aromatherapy significantly reduces pain severity in primary dysmenorrhea compared to placebo. A triple-blind RCT in 200 female students found a significant reduction in pain after two menstrual cycles of lavender inhalation. A separate RCT of 96 women confirmed significant relief from dysmenorrhea symptoms including abdominal pain, backache, and nausea.
At least two clinical trials — including a double-blind RCT — have demonstrated that lemon balm reduces the severity of primary dysmenorrhea. The herb's antispasmodic activity on uterine smooth muscle, mediated by calcium channel antagonism and rosmarinic acid, provides the mechanism. It also reduces the systemic symptoms of dysmenorrhoea (fatigue, lethargy, mood changes).
Multiple clinical trials and a Cochrane-linked review confirm magnesium is more effective than placebo for dysmenorrhea, reducing uterine muscle contractility by blocking calcium-dependent smooth muscle contraction. A systematic review and meta-analysis found magnesium contributes effectively to primary dysmenorrhea pain management. Traditional and integrative medicine have long recommended magnesium for menstrual cramping.
One controlled metabolic study found that lower dietary manganese intake was associated with increased pain symptoms during the menstrual phase, independent of calcium intake. Evidence is limited to a single small trial and requires replication.
A double-blind RCT of aromatic abdominal massage using a blend including marjoram essential oil in women with primary dysmenorrhea significantly reduced pain scores and shortened pain duration. Marjoram's antispasmodic properties are the proposed mechanism.
Peppermint has been tested in RCTs for primary dysmenorrhea. The mechanism involves menthol's antispasmodic effects on uterine smooth muscle via calcium channel blockade and TRPM8 activation. A crossover RCT compared peppermint capsules to mefenamic acid and showed comparable pain relief.
Morinda citrifolia (noni) was tested in a randomised double-blind placebo-controlled trial of 100 university students with primary dysmenorrhoea. The trial assessed pain scores, menstrual blood loss, and inflammatory markers over three menstrual cycles using 400 mg noni capsules.
C. rotundus (known as Xiangfu in TCM) is a primary traditional herb for primary dysmenorrhea, with scientific validation of its antispasmodic and anti-inflammatory mechanisms. It blocks calcium channels to relax uterine smooth muscle and inhibits prostaglandin pathways. TCM clinical formulations containing C. rotundus have been validated for dysmenorrhea.
A Cochrane-linked review and multiple RCTs demonstrate omega-3 fatty acids (fish oil) provide significant pain relief in primary dysmenorrhea compared to placebo, likely by shifting prostaglandin metabolism toward less pro-inflammatory eicosanoids. A 2022 systematic review and meta-analysis further confirmed their efficacy. Typical supplementation uses EPA+DHA fish oil for 2+ months.
Paeoniflorin, the primary active glycoside of peony root (Paeonia lactiflora), has demonstrated antispasmodic, anti-inflammatory, and analgesic effects in preclinical models relevant to primary dysmenorrhea. It inhibits uterine smooth muscle contraction and suppresses inflammatory cytokines. It is the principal bioactive compound underlying peony's traditional use in TCM for menstrual pain.
A multicenter, randomized, double-blind, placebo-controlled trial showed Pycnogenol (pine bark extract) significantly lowers the requirement for analgesic medication in dysmenorrhea. Clinical doses of 30–60 mg/day have been used. It is one of the well-supported gynecological indications in the American Botanical Council monograph.
A multicenter RCT and an open clinical trial both demonstrate Pycnogenol significantly reduces dysmenorrhea pain and analgesic medication use. The Journal of Reproductive Medicine (2008) RCT showed reduced pain and lower analgesic requirement. Mechanism involves spasmolytic action of phenolic acids and anti-inflammatory inhibition of prostaglandins.
A multicenter, randomized, double-blind, placebo-controlled trial showed Pycnogenol (French maritime pine bark extract) significantly lowered menstrual pain and reduced analgesic medication use in dysmenorrhea. An open clinical trial also confirmed significant pain score reduction. Pycnogenol inhibits inflammation and reduces prostaglandin-driven uterine cramping.
Rosa damascena extract showed comparable efficacy to mefenamic acid in reducing primary dysmenorrhea pain in a double-blind crossover RCT (n=92). A systematic review and meta-analysis of RCTs confirmed Rosa damascena reduces menstruation-related pain. Multiple additional RCTs support topical and aromatherapy use for dysmenorrhea.
R. cordifolia has been used clinically in Traditional Asian medicine for primary dysmenorrhea, and network pharmacology studies have revealed its mechanisms in improving blood clotting, circulation, arachidonic acid metabolism, and COX-2/cPLA2 inhibition relevant to menstrual pain. Many prescriptions containing R. cordifolia have been widely used in clinical treatment of primary dysmenorrhea in China.
Safflower has been used in TCM for over 2,500 years to relieve dysmenorrhea, regulate menstruation, and reduce menstrual pain. Modern pharmacological studies confirm that safflower extract and HSYA inhibit platelet aggregation, promote blood flow in the pelvic region, and stimulate ovarian granulosa cell proliferation. A comprehensive PMC review cites menstrual cramp relief among established clinical applications.
Saffron (Crocus sativus) and its active compounds (crocin, safranal) have been studied in clinical trials for PMS and dysmenorrhea. It is listed among herbs reported effective for dysmenorrhea and menstrual disorders in a PMC systematic review. Traditional Persian and Ayurvedic medicine have long used saffron as an emmenagogue and for menstrual pain.
Salicin-containing Salix extract has been studied against mefenamic acid for dysmenorrhea in a comparative clinical trial, with results favouring the willow extract. Traditional use for menstrual cramps (dysmenorrhea) is also well-documented across multiple cultures and ethnobotanical sources. The prostaglandin-inhibiting mechanism is directly relevant to uterine cramping.
CX is one of TCM's primary herbs for dysmenorrhea, with documented analgesic and antispasmodic effects. Animal model studies in dysmenorrhea have demonstrated analgesic efficacy of CX preparations. Ligustilide, the main smooth muscle relaxant in CX, acts on uterine smooth muscle, providing a pharmacological basis for antidysmenorrheic activity.
Multiple clinical trials from Iran and other countries have compared thyme preparations to ibuprofen for primary dysmenorrhea. A triple-blind RCT (PMC3992233) found Thymus vulgaris reduced dysmenorrhea symptom scores comparably to ibuprofen. The mechanism involves antispasmodic effects on uterine smooth muscle via thymol/carvacrol and inhibition of prostaglandin production.
A 2023 double-blind RCT and 2025 systematic review of RCTs support curcumin (the active compound in turmeric) for reducing primary dysmenorrhea pain and PMS symptoms. The turmeric–boswellia–sesame combination showed 12.6 times better total pain relief than placebo. Curcumin inhibits COX/LOX pathways and modulates prostaglandin synthesis.
One large RCT (n=556) found vitamin B1 (thiamine, 100 mg/day) significantly more effective than placebo for primary dysmenorrhea pain, and a 2014 double-blind RCT (n=240) confirmed it reduced both intensity and duration of dysmenorrhea pain. A systematic review of micronutrients for dysmenorrhea included vitamin B1 among effective interventions. It has been recommended in integrative medicine protocols.
Vitamin B6 has been studied for primary dysmenorrhea and premenstrual syndrome (PMS), with a pooled analysis of RCTs finding significantly higher odds of overall PMS symptom relief including cramping compared with placebo. Proposed mechanisms include modulation of prostaglandin synthesis and neurotransmitter balance.
Multiple clinical trials and a 2024 systematic review confirm vitamin D supplementation reduces the severity of primary dysmenorrhea, with a significant effect in meta-analysis (SMD −1.02, p=0.024). Lower serum vitamin D levels are inversely associated with dysmenorrhea severity. Vitamin D modulates calcium absorption and inflammatory cytokine production.
Clinical trials and a systematic review of micronutrients confirm vitamin E reduces primary dysmenorrhea pain severity, with a significant effect vs. placebo in meta-analysis (SMD −0.47, p=0.001). Vitamin E's antioxidant and prostaglandin-inhibiting properties underlie its mechanism. It has been evaluated both alone and in combination with fish oil in RCTs.
A 2019 retrospective cohort study (n=1700 women) found 85.2% of dysmenorrhea patients experienced menstrual pain improvement with Vitex agnus-castus extract over 3 months. It acts on dopamine and opioid receptors to reduce prolactin and modulate progesterone. Multiple RCTs support its use for PMS and menstrual cycle disorders including dysmenorrhea.
A randomized controlled clinical trial found that wheat germ extract (1,200 mg/day) significantly reduced pain severity in primary dysmenorrhea (P<0.001) compared to placebo, with proposed mechanisms involving prostaglandin reduction via vitamins B, D, E, magnesium, and zinc. A separate double-blind clinical trial also confirmed wheat germ's effectiveness on postpartum uterine cramping pain.
A randomized double-blind crossover clinical trial (Raisi Dehkordi et al., Complement Ther Med 2019, n=96) found that salix extract (400 mg/day) significantly outperformed mefenamic acid in reducing pain intensity (VAS) in primary dysmenorrhea. In the salix group, 77% of students showed no symptoms vs. only 45% in the mefenamic acid group. Drugs.com clinical pharmacology database and ESCOP both cite dysmenorrhea as a clinical indication supported by trial data.
A 2024 systematic review and meta-analysis of RCTs confirmed zinc supplementation significantly reduces pain severity in primary dysmenorrhea. Zinc inhibits prostaglandin production, upregulates superoxide dismutase 1, and improves endometrial microcirculation. Lower zinc levels have been observed in women with PMS and dysmenorrhea.
Painful menstruation (dysmenorrhea) is explicitly listed among the traditional ethnopharmacological indications of ajwain across Ayurvedic, Unani, and traditional Persian medicine. It is classified as 'Mudirr-i-Hayd' (emmenagogue) in Unani. No human clinical trials for menstrual pain exist.
Allspice has a well-documented traditional use for menstrual cramps across Caribbean, Central American, and Ayurvedic folk medicine. Eugenol's COX-inhibitory and prostaglandin-suppressing properties provide a plausible mechanism. Guatemalan ethnobotanical records specifically list it for menstrual cramps. No human trials exist.
Amber (Hu Po) has a documented TCM indication for dysmenorrhea (painful menstruation) attributed to blood stasis. The classical formula Hupo San uses amber as a key ingredient for menstrual pain. A clinical study of Modified Hupo San exists for cold-coagulation blood stasis dysmenorrhea, though amber is one of multiple herbs.
Black cohosh has a well-documented traditional use for menstrual cramps dating from Native American practice through 19th-century American eclectic medicine. The NCCIH confirms this historical use. Direct clinical trial evidence for dysmenorrhea as a primary endpoint is very limited.
Traditional European and Native American herbalism includes blackberry among remedies for menstrual pain, with documented use noted in multiple ethnobotanical sources. Blackberry's magnesium content and anti-inflammatory polyphenols provide mechanistic plausibility for cramp reduction.
Blessed thistle has been used traditionally as an emmenagogue and for relief of menstrual pain and cramps. Historical herbals and folk medicine consistently document this use, including for dysmenorrhea and amenorrhea. There is no clinical trial evidence supporting efficacy for menstrual pain.
Bromelain (a proteolytic enzyme from pineapple) is listed among herbs and enzymes reported to be effective for dysmenorrhea and menstrual disorders in a PMC systematic review of chamomile for dysmenorrhea. Its anti-inflammatory properties via prostaglandin inhibition are relevant. Traditional and complementary medicine have used it for inflammatory gynecological pain.
Buchu has been used as an antispasmodic and to stimulate or regulate menstrual flow in herbal traditions. Its antispasmodic properties are attributed to essential oil constituents. No clinical trials have evaluated buchu for dysmenorrhea or menstrual cramping.
In TCM, B. falcatum is used in formulas targeting uterine cramping and dysmenorrhea via its Liver Qi-moving and anti-inflammatory actions. It appears in classical formulas for menstrual pain and is included in contemporary multi-herb clinical formula trials for menstrual symptoms. Direct human clinical evidence for B. falcatum alone is absent.
Cajuput oil is used in traditional Malay medicine and aromatherapy for stomach cramps and as an antispasmodic, with references to menstrual cramp relief through massage. Its constituent 1,8-cineole has documented smooth-muscle relaxant properties via calcium channel inhibition. No clinical trials exist for this specific use.
Calendula (Calendula officinalis) is listed among herbs reported effective for dysmenorrhea and menstrual disorders in a PMC systematic review. Traditional European and Ayurvedic medicine have used calendula as an emmenagogue and antispasmodic for menstrual cramps. Its flavonoids (particularly quercetin derivatives) and triterpenoids provide anti-inflammatory properties.
Caraway has traditional use as an antispasmodic and emmenagogue in multiple herbal systems for menstrual cramps. Its smooth muscle relaxant properties are the proposed mechanism. One study is referenced in the literature showing caraway oil abdominal massage reduced menstrual pain, but formal high-quality clinical trials are not identified.
Cassia bark is widely documented in TCM, Ayurvedic, and folk medicine traditions as a warming herb used to relieve menstrual cramps and cold-type dysmenorrhea. No clinical trials specifically evaluating C. cassia for menstrual cramps were identified in the peer-reviewed literature.
A. aspera is used in Ayurveda and other traditional systems for dysmenorrhea (menstrual pain) and menstrual disorders. The plant's analgesic and antispasmodic properties may underpin this use. Scientific evidence is limited.
CQ has a documented history of use in Ayurvedic medicine for regulating menstruation and relieving menstrual pain. It is mentioned in traditional texts as a treatment for irregular menstruation and menstrual discomfort. RxList and ethnobotanical reviews acknowledge menstrual discomfort as a listed traditional use. No rigorous human clinical trials specifically evaluating CQ for menstrual cramps have been published.
Commiphora myrrh has a well-documented traditional classification as an emmenagogue across Ayurvedic, Unani, Chinese, and Arabic medicine systems. It was used for amenorrhea, dysmenorrhea, and pelvic inflammatory disease. No clinical RCTs for menstrual cramps have been identified.
Cramp bark (Viburnum opulus) has centuries of documented traditional use by Native American tribes (including Meskwaki) and European herbalists for menstrual cramps and dysmenorrhea. It contains scopoletin, aesculetin, and viburnin with demonstrated uterine antispasmodic activity in vitro. Modern clinical evidence is limited; it was official in the U.S. Pharmacopeia in 1894 and adopted by the 19th-century Eclectic medical movement for dysmenorrhea.
Cumin has been used across multiple traditional medical systems including Ayurveda, Iranian, and Egyptian medicine to relieve menstrual cramps and regulate menstrual cycles. Some sources suggest cumin may have mild estrogen-like effects. No human clinical trials on this specific indication exist.
Damiana is traditionally used in Mexican and Central American herbal medicine to ease menstrual discomfort. Its antispasmodic and muscle-relaxing properties, alongside GABA-modulating constituents, provide some mechanistic plausibility. No clinical studies on menstrual pain have been conducted.
Devil's Claw is traditionally used for menstrual problems among indigenous southern African peoples, documented in multiple ethnobotanical records. The PMC review (2022) lists it among its traditional uses. It was also used traditionally in childbirth contexts. No clinical trials address menstrual cramp relief specifically.
Wild yam (Dioscorea villosa) has a well-documented history of traditional use for dysmenorrhea, attributed to antispasmodic effects on uterine smooth muscle. It has been used since at least the 18th century for this purpose. Clinical trial evidence is absent.
Jamaican dogwood (Piscidia erythrina) has a well-established traditional use for dysmenorrhea and menstrual cramps, attributed to its antispasmodic activity on smooth muscle. It is cited in older pharmacopeias for this indication. Animal studies support antispasmodic mechanisms. No human clinical trials exist.
Dong quai (Angelica sinensis) is a central herb in Traditional Chinese Medicine, long used for menstrual irregularities and dysmenorrhea. Its ligustilide component relaxes uterine smooth muscle. It is classified as a uterine tonic and antispasmodic in TCM formulary, though standalone clinical RCT evidence for dysmenorrhea remains limited.
EPO has a well-documented history of traditional use for menstrual pain and dysmenorrhea, primarily in Western herbal medicine. The mechanistic rationale involves GLA-derived prostaglandin modulation, as excess pro-inflammatory prostaglandins (PGE2, PGF2α) are the principal drivers of primary dysmenorrhea. Clinical trial evidence specifically for primary dysmenorrhea remains sparse.
Asafoetida is classified as antispasmodic and emmenagogue in Ayurvedic, Unani, and Iranian medicine and is specifically used for painful menstruation (dysmenorrhea) and uterine cramps. Smooth muscle relaxant activity confirmed in guinea pig ileum studies supports the mechanistic basis for uterine antispasmodic effects.
Feverfew has been used since antiquity to relieve menstrual pain and cramping, with documented use in Greco-Roman medicine and in multiple folk traditions. Its antispasmodic and prostaglandin-inhibiting properties provide a mechanistic rationale. No dedicated clinical trials exist for this specific indication.
Forskolin's potent smooth-muscle relaxant (antispasmodic) action, mediated by cAMP elevation in uterine smooth muscle, underpins long-documented Ayurvedic use of C. forskohlii for dysmenorrhea. No human clinical trials have specifically evaluated the herb for menstrual cramps.
Geranium has a documented traditional use as an antispasmodic for menstrual cramps. It is listed in multiple ethnobotanical reviews as used for menstrual problems including pain and spasm. No dedicated human RCTs specifically for dysmenorrhea have been identified.
Guggul is noted in Ayurvedic and clinical literature as a uterine stimulant that encourages menstrual flow (emmenagogue), and is used in formulations for menstrual disorders including dysmenorrhea. It is contraindicated in pregnancy for the same reason. No clinical trials for dysmenorrhea are available.
Horse chestnut seed extract has a documented traditional use for menstrual pain (dysmenorrhea) in both Western and traditional Chinese medicine contexts. The NCCIH confirms this as a traditional indication. No human clinical trials specifically studying HCSE for menstrual cramps have been identified in the literature.
Kava has a documented traditional and herbal-medicine use as an antispasmodic for menstrual cramps, attributed to its smooth-muscle relaxant and anxiolytic properties. Kavalactones have demonstrated spasmolytic activity on smooth muscle in preclinical models, consistent with this use. No dedicated human RCT has tested kava specifically for dysmenorrhea.
Lemongrass is traditionally used across several communities as an emmenagogue and to relieve dysmenorrhea pain. A 2025 preclinical study validated this use in a rat model of primary dysmenorrhea, finding C. citratus extract inhibited COX and LOX enzymes and relaxed uterine muscle. Traditional use is widely documented; human clinical trials are absent.
Magnolia bark has been used in TCM for menstrual pain and dysmenorrhea, attributed to its antispasmodic and anti-inflammatory properties. Preclinical evidence supports muscle-relaxant effects, and anti-inflammatory activity via NF-κB and cytokine suppression provides a mechanistic rationale. No dedicated human RCTs for menstrual cramps exist.
Milkweed, especially A. tuberosa, was used in 19th-century Eclectic medicine for menorrhagia (excessive menstrual bleeding) and as an antispasmodic for uterine complaints. The antispasmodic property was considered applicable to menstrual cramping. No clinical evidence exists for this use.
Momordica charantia is recorded as a traditional treatment for dysmenorrhea (menstrual cramps) and as an emmenagogue across Ayurvedic, Chinese, Caribbean, and African folk medicine. No human clinical trials have investigated this use.
Mugwort (Artemisia vulgaris) is one of the oldest traditional herbal remedies for menstrual cramps and irregularity, used as an emmenagogue and antispasmodic across East Asian, European, and indigenous traditions. It is used in Traditional Chinese Medicine (moxibustion and internal) specifically for cold-type dysmenorrhea. Scientific clinical trial evidence for oral use in dysmenorrhea is limited.
Muira puama has documented traditional use across Amazonian, European, and British herbal medicine for menstrual disorders including cramps. It is listed in the British Herbal Pharmacopoeia and used in Germany for menstrual disturbances. No controlled clinical evidence for this specific indication exists.
Myrrh has been used as an emmenagogue and analgesic for menstrual cramps and amenorrhea across TCM, Ayurveda, and Western herbal traditions. In TCM, it is categorized as moving stagnant blood from the uterus to relieve painful menstruation. No dedicated human clinical trials exist.
Oregano has centuries of documented use as an emmenagogue (stimulating menstrual flow) and antispasmodic for menstrual cramps in Mediterranean, European, and Middle Eastern folk medicine. The 19th-century Eclectic School of physicians used it specifically to promote menstruation. No controlled human clinical trials have evaluated oregano for dysmenorrhea.
Oriental arborvitae is documented in NLM/RxList sources as traditionally used for menstrual cramps. Its anti-inflammatory properties provide a plausible mechanism. TCM anti-inflammatory and blood-regulating classification is consistent with this use.
Parsley is used in traditional medicine specifically for dysmenorrhoea (painful periods), with apiol and myristicin acting as uterine smooth muscle modulators. Herbal references document its spasmolytic and anti-inflammatory actions relevant to cramp reduction. No human clinical trials exist for this endpoint.
Menstrual cramps is among the oldest recorded uses of feverfew, with the plant's very name 'parthenium' possibly derived from its Greco-Roman use in treating menstrual pain in young women. Its antispasmodic and prostaglandin-inhibiting properties provide pharmacological plausibility. Clinical trials are absent.
Passionflower is documented in traditional herbal medicine as an antispasmodic used for painful menstruation (dysmenorrhea). The PMC systematic review (Kaźmierczyk et al., 2020) lists 'painful menstruation' among its traditional applications, and EBSCO Research Starters lists menstrual cramps among proposed therapeutic uses. The mechanism invoked is smooth-muscle relaxation via antispasmodic and anxiolytic activity; no dedicated RCTs for menstrual cramps are on record.
Peach kernel (Tao Ren) is a key TCM ingredient for dysmenorrhea (painful menstruation) associated with blood stasis. It is used in multiple classical formulas specifically indicated for menstrual pain with dark, clotted blood. No human clinical trials exist for peach kernel alone.
Thlaspi arvense is recorded in traditional Chinese medicine for the treatment of dysmenorrhea and post-partum pain. European folk medicine also noted the plant's utility for menstrual complaints. No human clinical trials have been conducted.
Peony root (Paeonia lactiflora) is a classical TCM herb used in the foundational formula Si Wu Tang for dysmenorrhea and menstrual irregularity. Paeoniflorin, its active compound, has antispasmodic, anti-inflammatory, and analgesic properties demonstrated in preclinical studies. It is a cornerstone gynecological herb in East Asian medicine with limited standalone RCT data.
Bromelain from pineapple has a documented traditional use for menstrual cramps, attributed to its ability to relax smooth muscle and reduce prostaglandin-driven inflammation. Restorative medicine monographs include menstrual cramps among traditional indications, though dedicated clinical trials are absent.
Southern prickly ash (Z. clava-herculis) has documented traditional use for menstrual cramps, listed in RxList and multiple materia medica texts. Prickly ash is classified as an antispasmodic and emmenagogue in traditional herbalism, properties that underlie its use for menstrual pain. No human clinical evidence supports this use.
Queen of the meadow has been traditionally used as an antispasmodic and analgesic for menstrual pain, attributed to its salicylate and flavonoid content acting as smooth muscle relaxants and anti-inflammatory agents. This use is recorded in herbalist traditions but has not been investigated in clinical trials.
Raspberry leaf is one of the most longstanding herbal remedies for dysmenorrhea (menstrual cramps), referenced in European and Native American herbal traditions. The proposed mechanism involves fragarine, an alkaloid that tones and tightens pelvic smooth muscles, reducing cramping spasms. The tannin content is further credited with supporting uterine tissue. No controlled clinical trials specifically assessing raspberry leaf for dysmenorrhea pain scores have been published.
Rehmannia is listed in TCM monographs for dysmenorrhea (painful menstruation), where it nourishes Blood and reduces the deficiency-type cold and stagnation underlying menstrual pain. It appears in classical formulas for this purpose but no standalone clinical trials exist.
Rhubarb root is documented in traditional Chinese medicine for dysmenorrhea (menstrual cramps) and amenorrhea, attributed to its blood-activating and stasis-eliminating properties. EBSCO and TCM references confirm this traditional use; no specific modern RCTs for menstrual cramps with rhubarb monotherapy were identified.
Rosemary (Rosmarinus officinalis/Salvia rosmarinus) is listed among herbs reported effective for dysmenorrhea and menstrual disorders in a PMC systematic review. Traditional European and Middle Eastern herbal medicine have used rosemary as an emmenagogue and antispasmodic for menstrual pain. Its rosmarinic acid, carnosic acid, and flavonoid content provide anti-inflammatory properties.
Sage has a documented traditional use for menstrual cramps and dysmenorrhea across multiple herbal traditions, attributed to its antispasmodic properties. No dedicated human clinical trials evaluating sage specifically for menstrual pain could be identified in peer-reviewed literature.
Sarsaparilla has documented traditional use for menstrual disorders including cramps and irregular cycles across South American, Mexican, and Asian herbal systems. EBSCO Research Starters and PeaceHealth both document this traditional indication. No clinical trials for dysmenorrhea or menstrual pain have been conducted.
Shepherd's purse is traditionally used as a uterine astringent and smooth muscle modulator for gynecological bleeding, and herbalists have historically extended its use to dysmenorrhoea. Its uterotonic and antispasmodic-adjacent activity is attributed to oxytocin-like peptides and biogenic amines, but no clinical trials specifically address menstrual pain.
Cherokee and other Native American tribes used S. lateriflora extensively for menstrual disorders, and Indigo Herbs notes its antispasmodic activity makes it effective for menstrual cramps. The NIH LiverTox confirms centuries of Native American use for menstrual disorders. No clinical trials specific to menstrual cramps exist.
Dysmenorrhea (menstrual cramps) is documented as a traditional use of P. hydropiper leaf juice across South Asian ethnomedicine. The plant is also classified as an emmenagogue, reflecting its broad gynecological traditional application.
Solomon's seal is used in traditional Western herbal medicine and indigenous North American traditions for menstrual cramps (dysmenorrhea). The herb's antispasmodic and mild sedative properties, attributed to allantoin and saponins, are cited as the mechanism.
Squawvine has a well-documented traditional use for dysmenorrhea across Native American tribes and in Eclectic and naturopathic medicine. It is classified as an antidysmenorrhoeic and uterine relaxant. The tannins and saponins in the plant are proposed to contribute to smooth-muscle-relaxing and anti-inflammatory actions. No human clinical studies exist.
Valerian root (Valeriana officinalis) has traditional use as an antispasmodic and sedative for uterine cramping and is listed among antispasmodic herbs for dysmenorrhea in Western herbal medicine. Limited clinical research exists; one small RCT suggested benefit for dysmenorrhea pain. Its valerenic acid components act on GABA receptors and have smooth muscle relaxant activity.
Vanilla has a documented traditional use for dysmenorrhea (menstrual cramps) across Mesoamerican and European herbal traditions. The Drugs.com monograph and Nutrition Today review both cite dysmenorrhea as a traditional vanilla indication. Vanilla's antispasmodic properties are the proposed mechanism. No clinical or preclinical studies have specifically investigated this use.
White willow bark has been used traditionally for dysmenorrhea (menstrual cramps), and its prostaglandin-inhibiting mechanism provides a pharmacological rationale analogous to NSAIDs. It is listed among conditions treated with willow bark in multiple authoritative references. No dedicated clinical trials for dysmenorrhea have been conducted.
Wild yam (Dioscorea villosa) has been used in North American traditional herbal medicine as an antispasmodic for uterine cramping and dysmenorrhea. It is classified as an antispasmodic and uterine relaxant in Western herbalism. Scientific evidence for direct hormonal or clinical dysmenorrhea effects in humans is limited.
Wood betony is documented in Western herbalism as an emmenagogue and antispasmodic for menstrual cramps and uterine congestion. Traditional texts and modern herbalists consistently list it for period pain, especially cramping with dark blood and clots.
Yarrow (Achillea millefolium) is listed among herbs reported effective for dysmenorrhea and menstrual disorders in a PMC systematic review. It has been used as an emmenagogue and antispasmodic for menstrual cramps in European and indigenous North American herbal traditions for centuries. Its flavonoids and alkaloids provide anti-inflammatory and antispasmodic activity.
Go back